Neurocrine Biosciences, Inc.

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Novo Nordisk, IMMvention Collaboration

Teva may grapple with questions about how its Austedo (deutetrabenzene) is worth the price premium over generic tetrabenzene while negotiating a “maximum fair price” with the US Centers for Medicare

This year has posed substantial challenges for global markets: a prolonged period of high interest rates, ongoing geopolitical instability, democratic uncertainty, and an unprecedented number of natio

Neurocrine Biosciences will soon launch its second wholly owned commercial product, Crenessity (crinecerfont) for classic congenital adrenal hyperplasia (CAH), adding what the company sees as another